| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$41.5M | ROE | −52.46% |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $408.5M | Trading Days | 2749 |
| 52W High | 16.76 |
| 52W Low | 9.85 |
| % Off High | −29.06% |
| YTD | −11.73% | 1Y | 7.89% |
| 3Y | 276.27% | 5Y | −80.89% |
| 10Y | −97.33% | Since incept. (ann.) | −37.46% |
| Ann. Volatility (1Y) | 56.95% | Ann. Volatility (3Y) | 85.51% |
| Sharpe (1Y) | 0.43 | Sharpe (3Y) | 0.89 |
| Max Drawdown (1Y) | −39.10% | Max Drawdown (3Y) | −43.07% |
| Beta (3Y, vs SPY) | −0.66 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| EOLS | Evolus, Inc. | $409.6M | — |
| ASMB | ASSEMBLY BIOSCIENCES, INC. | $406.4M | — |
| PBYI | PUMA BIOTECHNOLOGY, INC. | $405.7M | 13.1 |
| EVMN | Evommune, Inc. | $405.2M | — |
| ELTP | ELITE PHARMACEUTICALS INC /NV/ | $403.9M | 12.5 |
| LRMR | Larimar Therapeutics, Inc. | $397.9M | — |
| KROS | Keros Therapeutics, Inc. | $381.2M | 4.4 |
| CAPR | CAPRICOR THERAPEUTICS, INC. | $380.5M | — |
| OVID | Ovid Therapeutics Inc. | $440.5M | — |
| EBS | Emergent BioSolutions Inc. | $377.2M | 7.9 |
| PRTA | PROTHENA CORP PUBLIC LTD CO | $448.1M | — |
| PRLD | Prelude Therapeutics Inc | $369.6M | — |
